U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H32N2O
Molecular Weight 328.4916
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 77-LH-28-1

SMILES

CCCCC1CCN(CCCN2C(=O)CCC3=CC=CC=C23)CC1

InChI

InChIKey=PHMGZAICAOYEAF-UHFFFAOYSA-N
InChI=1S/C21H32N2O/c1-2-3-7-18-12-16-22(17-13-18)14-6-15-23-20-9-5-4-8-19(20)10-11-21(23)24/h4-5,8-9,18H,2-3,6-7,10-17H2,1H3

HIDE SMILES / InChI

Molecular Formula C21H32N2O
Molecular Weight 328.4916
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/21964721 | https://www.ncbi.nlm.nih.gov/pubmed/20600173

77-LH-28-1 Oxalate is a salt of 77-LH-28-1. This drug is a potent, selective, bioavailable and brain-penetrant agonist of muscarinic acetylcholine receptor subtype 1. 77-LH-28-1 can increase network oscillations relevant to cognitive processing that would support the potential use of this mechanism in the treatment of cognitive impairment. 77-LH-28-1 exhibited U-shaped dose-effect functions in attenuating cocaine discrimination. 77-LH-28-1, can significantly enhance donepezil-induced gamma oscillations. These data support the notion that it should be possible to find a more efficacious AChE inhibitor or an adjunctive approach, to provide a better therapeutic intervention in Alzheimer's disease.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
2008 Jul
Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.
2014 Aug 22
Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1).
2014 Nov 13
Patents

Sample Use Guides

3 mg/kg
Route of Administration: Other
77-LH-28-1 was assessed for their ability to initiate single-unit cell firing in the CA1 region of the rat hippocampus. 77-LH-28-1 stimulated single-unit firing, acting as a full agonist with respect to carbachol, with a pEC50 value of 6.3.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:11:29 GMT 2023
Edited
by admin
on Sat Dec 16 17:11:29 GMT 2023
Record UNII
9ZH28BM589
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
77-LH-28-1
Common Name English
2(1H)-Quinolinone, 1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-
Systematic Name English
77LH28-1
Common Name English
1-(3-(4-BUTYLPIPERIDIN-1-YL)PROPYL)-3,4-DIHYDRO-1H-QUINOLIN-2-ONE
Systematic Name English
Code System Code Type Description
PUBCHEM
10236758
Created by admin on Sat Dec 16 17:11:29 GMT 2023 , Edited by admin on Sat Dec 16 17:11:29 GMT 2023
PRIMARY
WIKIPEDIA
77-LH-28-1
Created by admin on Sat Dec 16 17:11:29 GMT 2023 , Edited by admin on Sat Dec 16 17:11:29 GMT 2023
PRIMARY
CAS
560085-11-2
Created by admin on Sat Dec 16 17:11:29 GMT 2023 , Edited by admin on Sat Dec 16 17:11:29 GMT 2023
PRIMARY
FDA UNII
9ZH28BM589
Created by admin on Sat Dec 16 17:11:29 GMT 2023 , Edited by admin on Sat Dec 16 17:11:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID90437063
Created by admin on Sat Dec 16 17:11:29 GMT 2023 , Edited by admin on Sat Dec 16 17:11:29 GMT 2023
PRIMARY